|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
NASDAQ DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … UPDATE 1-EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News